People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology, Pharmaceuticals, Other Technology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Camp4 Therapeutics Corp | — | Biotechnology | Series D+ | $179.6M | $2.2B | 2018 |
| Genocea Biosciences, Inc. | — | Biotechnology | Series C | $153.6M | $3.0B | 2019 |
| Voyager Therapeutics, Inc. | — | Biotechnology | Series C | $119.0M | $215.1M | 2024 |
| Nocion Therapeutics, Inc. | — | Pharmaceuticals | Series B | $76.1M | $90.4M | 2024 |
| Pulmatrix Inc | — | Biotechnology | Series B | $69.6M | $396.9M | 2015 |
| Pulmatrix, Inc. | — | Pharmaceuticals | Series B | $62.9M | $86.1M | 2015 |
| Arria NLG PLC | — | Other Technology | Series C | $52.2M | $54.1M | 2012 |
| Stage I Diagnostics, Inc. | — | Biotechnology | Pre-Seed | $1.0M | $5.6M | 2009 |
| GFM Holdings, LLC | — | Other | Pre-Seed | $750K | $17.3M | 2016 |
Michael Higgins at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Higgins on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 2 | 23 |
| SCOTT ROCKLAGE | 2 | 9 |
| Terrance McGuire | 2 | 9 |
| Robert Clarke | 2 | 7 |
| Kurt Graves | 2 | 5 |
| David Hava | 2 | 2 |
| David Maki | 2 | 2 |
| Asish Xavier | 1 | 18 |
| Ali Behbahani | 1 | 17 |
| Kevin Bitterman | 1 | 15 |
| LEON CHEN | 1 | 15 |
| Amir Nashat | 1 | 14 |
| William Clark | 1 | 12 |
| Mark Levin | 1 | 9 |
| Simeon George | 1 | 8 |
| Andrew J. Schwab | 1 | 7 |
| Mitchell S. Bloom | 1 | 7 |
| Stephen Hoffman | 1 | 7 |
| Amit Munshi | 1 | 5 |
| Stuart Rogers | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.